Possible Tx N2 M0 atypical bronchial carcinoid associated with Cushing syndrome  by Filosso, Pier Luigi
Letters to the
Editor
Possible Tx N2 M0 atypical
bronchial carcinoid associated with
Cushing syndrome
To the Editor:
Although bronchial carcinoids (BCs) ac-
count for only 1% of cases of Cushing
syndrome (CS),1 in many cases the ectopic
adrenocorticotropic hormone production
has a source within the thorax. Usually
typical BCs are the cause of ectopic CS, but
rarely atypical ones have been described.
BCs associated with CS appear more ag-
gressive than others, with high tendency to
metastasize.2
The article of Sugawara and col-
leagues,3 “Successful Localization and
Treatment for Ectopic Adrenocorticotro-
phic Hormone Secretion in a Rare Case
of Possible Tx N2 M0 Carcinoid Tumor
With Cushing Syndrome,” is interesting
and highlights the importance of a correct
management of a patient with ectopic CS.
I have some questions for the authors:
1. Why did they not perform a medias-
tinoscopy before 2001, rather than
video-assisted thoracoscopic lymph
nodal resection?
2. Why was scintigraphy with indium
In-111 pentetreotide (OctreoScan)
performed only in 2001 and not ear-
lier?
3. Why was the surgical resection was
performed by thoracoscopy and not
by thoracotomy?
4. Was the patient subjected to any ad-
juvant therapy?
5. Was OctreoScan scintigraphic fol-
low-up planned or not?
I think that any pulmonary or mediasti-
nal masses should be investigated in case
of suspected ectopic adrenocorticotropic
hormone production, and OctreoScan scin-
tigraphy represents the most effective diag-
nostic tool and should be performed early.
I think that thoracotomy should have been
preferred for mediastinal lymphadenec-
tomy because of the possibility of achiev-
ing a radical resection of the nodes and the
possibility of an accurate lung palpation to
detect possible small pulmonary nodules.
Shrager and associates2 confirm that the
use of video-assisted thoracoscopic resec-
tion in BC with CS would be inappropriate.
In cases of N2 atypical BC, adjuvant ther-
apy is mandatory because of the risk of
local relapses or distant metastases. Marty-
Ane´ and coworkers4 suggest chemother-
apy, but medical therapy with octreotide
could be considered too. Octreotide, in
fact, binds with high affinity to subtype 2
somatostatin receptors that are present in
neuroendocrine cells surface, exerting a
growth inhibitory effect in neuroendocrine
tumors. Octreotide could be considered as
an effective biologic postoperative therapy,
generally well-tolerated and without im-
portant side effects. Using the long-acting
form of this drug, only a single administra-
tion every 28 days is required. Finally Oc-
treoScan scintigraphy is mandatory for the
follow-up, because it has been demon-
strated to be effective in detecting recur-
rences earlier than traditional radiologic
procedures.5
Pier Luigi Filosso, MD
Department of Thoracic Surgery
San Giovanni Battista Hospital
University of Torino
Torino, Italy
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Reply to the Editor:
We read with interest the letter by Filosso
from the University of Torino. When the
patient came to our department, we had
questions similar to those that Filosso
posed.
In Japan, scintigraphy with indium In-
111 pentetreotide (OctreoScan) is still only
available for research purposes, not for
clinical use. This is one of the reasons why
we did not perform the scan before 2001,
nor did we after the operation.
As Filosso mentioned, it is thought
that bronchial carcinoid producing adre-
nocorticotropic hormone is aggressive.1
However, our patient showed a different
clinical course, as we reported. More
than 5 years passed between the onset of
symptoms and her operation. Despite her
long follow-up duration, no change in
the size of mediastinal nodes was de-
tected by serial examination until 2001.
This may be the reason that her physician
hesitated to consult us. In addition, the
levels of adrenocorticotropic hormone
and cortisol had not become worse during
her course.
With regard to the use of a mediastino-
scope, we also believe that this procedure is
a useful method to localize and diagnose a
tumor. However, with this procedure, it is
sometimes difficult to perform en bloc re-
moval of the whole tumor. We were also
afraid that piece by piece removal might
cause an intraoperative crisis of Cushing
syndrome. In addition, our previous stud-
ies2,3 showed that removal of lymph nodes
could be completed under thoracoscopic
surgery. Our data revealed that only 2% of
lymph nodes in weight could not be re-
moved when performing sequential thora-
cotomy just after thoracoscopic surgery.
Regarding the region of pretracheal and
paratracheal lymph nodes, no residual
lymph nodes were detected in our studies.
So in our case, we chose thoracoscopic
surgery.
As mentioned by Filosso, we also be-
lieve that any pulmonary masses should be
investigated in case of suspected ectopic
adrenocorticotropic hormone production.
However, we did not detect any tiny le-
sions in either lung on thin-sliced com-
puted tomographic images. In such case,
should we perform bilateral thoracotomy?
We informed our patient, and she chose
thoracoscopic resection. We also told her
and her family about the possible need for
further surgery should a new lung mass
shadow develop.
Octreotide is also a good alternative
option for adjuvant therapy in cases of
stage III carcinoid tumor after surgery to
prevent recurrence.4,5 Before our pa-
tient’s operation, she received octreotide
treatment for about 1 year. She refused to
continue the treatment, however, because
of pain caused by subcutaneous injection.
Now 2 years have passed since her oper-
ation. She is doing well without any signs
of recurrence; the values of hormones are
within normal ranges, and no abnormal
mass has been detected by whole-body
screening.
Finally, we appreciate Filosso’s advice.
He advised us to implement a follow-up
plan including OctreoScan scintigraphy
and possible octreotide treatment. Consid-
ering his advice, we will discuss her adju-
vant therapy and follow-up plan with her
physicians and perform careful and inten-
sive follow-up.
Takafumi Sugawara, MD
Masami Sato, MD
Shulin Wo, MD
Takashi Kondo, MD
Tohoku University
Sendai, Japan
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Spiral pattern: Universe, normal
heart, and complex congenital
defects
To the Editor:
In the fascinating article “Basic Science
Review: The Helix and the Heart”1 in a
recent issue of Journal, Gerald Buckberg,
supported by the anatomic studies of Tor-
rent-Guasp and colleagues,2 illustrated the
spiral anatomy of the muscle bands and the
helicoid shape of the myocardium. On the
basis of recent observations on embryology
and genetics, we have reached similar con-
clusions regarding the spiral pattern of the
heart morphology in complex congenital
defects.3
The normal heart has a clockwise spiral
pattern of the outflow tracts and of the great
arteries. The helicoid 3-dimensional move-
ment driving to this condition, genetically
determined in subjects with situs solitus,
appears with the dextroventricular loop
(right ventricle to the right, left ventricle to
the left),4 progresses with the looping (an-
terior rotation of the right ventricle, poste-
rior rotation of the left ventricle), and fin-
ishes with the spiral septations of the
outflow tracts and the great arteries.5 Be-
cause the dextroventricular loop is the first
recognized sign of asymmetry and lateral-
ization of the body organs,4 the clockwise
spiralization of the heart should be consid-
ered a specific pattern of chirality in verte-
brates. In subjects with situs inversus, an
incompletely understood genetic mecha-
nism6 is responsible for a “mirror image”
anatomy of the heart, with counterclock-
wise shape of the outflow tracts and great
arteries. This condition appears with a
Letters to the Editor
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 4 1225
